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Summary: Using an ELISA assay anti-nuclear antibody-positive sera from 300 patients with various immune-
related diseases and 64 anti-nuclear antibody-negative sera were analysed for binding to Sl-nuclease-treated double
stranded (ds) DNA. In addition, the pattern of reactivity of 50 selected anti-dsDNA-positive sera was established
using denatured (d) DNA and poly[dA-dT] X poly[dA-dT] double-stranded alternating copolymer (dAT) as addi-
tional DNA antigens. None of the 64 anti-nuclear antibody-negative sera and 76 of the 300 anti-nuclear antibody-
positive sera (25%) were anti-dsDNA-positive. Of the anti-nuclear antibody-positive and anti-dsDNA-positive sera,
48 (63%) were from systemic lupus erythematosus patients, and 7 (9%) from rheumatoid arthritis patients, whereas
21 patients (27.6%) suffered from various immune and non-immune related diseases. Anti-dsDNA-positive reactiv-
ity was highly correlated with dDNA and dAT reactivity (r = 0.906, p < 0.0001 and r = 0.93, p < 0.0001, respec-
tively). Although the majority of the 50 selected (37 systemic lupus erythematosus and 13 non-systemic lupus
erythematosus) anti-dsDNA-positive sera concomitantly bound to both additional antigens, 7 of these (14%) did
not bind to dAT, and 2 (4%) did not bind to dDNA. Anti-dsDNA-positive sera (n = 37) showed a similar pattern,
in which 8.1% and 2.7% of sera did not bind to dAT and to dDNA, respectively. In contrast, anti-dsDNA-negative
sera from various immune-related diseases bound either ssDNA (12.5%) or dDNA and dAT (12.5%). These data
suggest that dsDNA and dAT-based assays detect similar but not identical specificities in the sera of patients
suffering from systemic lupus erythematosus and in a proportion of non-systemic lupus erythematosus patients.
Introduction variety of diseases and have no diagnostic importance
A .M ,- · . Λ t , . Λ j ,A ^ ΤΛΧΤΑ f Λ (4). An intriguing hypothesis has been proposed thatAntibodies against double stranded (ds) DNA are found v ' ^ . 6 . , . , , „ ,
in 50% to 75% of patients with systemic lupus erythe- »^-affimly anti-ssDNA') arise as a by-product of poly-
matosus, and they represent one of the most helpful clonal actlvatlon dunnS imtial staSes of systeirac luPus
,
 f ,. . . ! ., erythematosus, whereas anti-dsDNA antibodies emergemarkers for diagnosing systemic lupus erythematosus , . ,. . .
(reviewed in 1. c. (1)). In addition to their diagnostic po- *™°* ***?" P^88'0* ^  the Process of antlSen'
tential, these antibodies are associated with the develop- dnven selectlon of B'cells (5)'
ment of renal complications in systemic lupus erythema- DNA is a rather flexible molecule that may adopt dif-
tosus patients (2). Although anti-dsDNA1) antibodies are ferent conformational forms (2, 6, 7). Even purified
a central feature of systemic lupus erythematosus and dsDNA (which constitutes 85% of native DNA ex-
are thought to play a role in its pathology, they have tracted from cells) can take up different conformations,
also been found with lower frequency and in lower titre and further variations can be induced by temperature,
in normal sera and in sera from patients with other auto- pH and ion concentration. Thus, these conditions may
immune diseases (1—4). In contrast, antibodies to sin- influence the binding of antibodies to their target antigen
gle-stranded (or denatured) DNA (dDNA1)) occur in a (7). Early observations revealed that sera from systemic
_ lupus erythematosus patients reacted with ssDNA,
1}
 Abbreviations· dsDNA or with both forms, but the analysis of the fine
dAT, poly[dA-dT] X po!y[dA-dT] double-stranded alternating co- specificity of DNA by monoclonal antibodies showed
polymer;
 an extremely diverse fine specificity of DNA antibodies
dsDNA, double-stranded deoxyribonucleic acid; ,0. T. . n . . , ., . .. , ,-^ΧΤΑ *-u j·dDNA, denatured DNA; (8)· ft 1S wel1 aPPreciated that anti-dsDNA antibodies
ssDNA, single stranded'DNA. have little specificity for base sequences (1,8) and bind
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to the epitopes centred on the phosphate backbone of
the dsDNA. In contrast, the anti-DNA antibodies re-
active with bases are found primarily among antibodies
reactive with ssDNA or denatured DNA, where the
bases are exposed (7).
ELISA is one of the most adequate techniques for the
clinical measurement of the anti-dsDNA level (9). How-
ever, since preparing and maintaining an antigenically
pure dsDNA is not an easy task in the routine determina-
tion of anti-sDNA, synthetic molecules, such as alternat-
ing double stranded dAT1) copolymer, were proposed as
model molecules for an additional anti-native DNA as-
say ((10) and reviewed in I.e. (11)). The rationale was
the observed high correlation between native DNA and
dAT-binding and the absence of contaminating mole-
cules in the synthetic antigen (10). However, others have
shown that systemic lupus erythematosus serum may
have antibodies against different native DNA epitopes,
i. e. those against the structure found in native DNA and
those found in synthetic antigen (double helical configu-
ration) (reviewed in I.e. (11)). In this study, we report a
solid-phase assay for determination of antibodies against




This group consisted of 64 adult (> 15 years of age) individuals
of both sexes (c? : $ 1 : 2), whose sera gave a negative reaction for
anti-nuclear antibodies in the immunofluorescent assay on rat liver
sections. In general, these samples showed no abnormal findings
during routine checking of immunological quantities, including to-
tal haemolytic activity, C3, C4, Clq, circulating immunocom-
plexes, rheumatoid-factor, anti-nuclear antibodies, anti-neutrophil
cytoplasm antibodies and C-reactive protein.
Study group
These subjects were selected on the basis of their positive anti-
nuclear antibody reaction (serum dilution > 1 : 16) and consisted
of 300 adult subjects of both sexes with a male : female ratio of
1 : 4.8. Immunological testing was performed either as part of an
out-patient diagnostic procedure or during hospitalisation of
patients for treatment at the University Hospital Centre, Zagreb.
This group consisted of patients with various diagnoses of autoim-
mune and non-autoimmune conditions, including degenerative, in-
flammatory and malignant diseases. All patients with autoimmune
diseases were classified and diagnosed according to standard cri-
teria (American Rheumatology Association criteria) (12-14).
Patients with autoimmune diseases were either in active or inactive
phase of disease. In order to avoid any bias toward a particular
diagnosis, the sera were tested blindly, without prior knowledge of
the patient's diagnosis. After the results of the ELISA were known,
the diagnoses were obtained from responsible physicians, and sera
from dsDNA"4" patients were checked in the DNA ELISA.
Sera
All samples were centriftiged immediately after receipt, heated (30
min at 56 °C) and stored at -20 °C (4-6 weeks) or at -70 °C
(> 6 weeks).
Anti-nuclear antibody testing
The test was performed on acetone-fixed rat liver sections using
FITC-labelled goat anti-human polyvalent Ig(A+G+M) (Imuno-
loski Zavod, Zagreb, Croatia) as a second layer. The slides were
analysed under a fluorescence microscope (Carl Zeiss, Jena, Ger-
many) equipped with an epi-illuminator.
Immunoblot-assay for autoantigehs
In the majority of patients, a panel for the detection of autoantigens
(ANA, dsDNA, SS/A, SS/B, Sm/RNP)2) was performed using an
ImmunoDot assay (Gen Bio, San Diego, CA, USA).
Reagents and materials
Deoxyribonucleic acid from calf thymus (Sigma, Cat. #D3664),
polydeoxyadenylic-thymidylic acid (poly[dA-dT] x poly[dA-dT])
(Cat. #Po883), methylated bovine serum albumin (Cat, #A-1009),
nuclease-Sl from Aspergillus oryzae (Cat. #N7385), calf serum
(Cat. #C6278), bovine serum albumin (Cat. #A2153), affmity-
purified and alkaline phosphatase-conjugated anti-human polyva-
lent immunoglobulins (α, γ and μ-chain specific) (Cat. #A5034),
polyoxyethylenesorbitan (Tween-20 (Cat. #P2690)) and /7-nitro-
phenyl phosphate disodium (Cat. #N2765) were purchased from
Sigma, USA. All other chemicals - NaCl, sodium acetate
(CH3CO2Na), NaOH, ZnCl2, ethanolamine (H2NCH2CH2OH) and
NaH2PO4 X 2H2O - were purchased from Kemika, Zagreb, Croa-
tia. The 96-well microtitre assay plates included Falcon PVC
Microtest III (Cat. #3912) and PRO-BIND plates (Cat. #3915)
(Becton Dickinson and Co., Oxnard, Canada) and 96-well flat bot-
tomed plates from Behringwerke AG, Marburg, Germany. The ab-
sorbance was read using a Behring ELISA Processor (Beh-
ringwerke AG, Marburg, Germany).
Preparation of dsDNA
Double stranded DNA was prepared according to the original
method of Rubin (15). Briefly, native DNA from calf thymus was
dialysed against acetate buffer (0.03 mol/1 sodium acetate, 0.1
mol/1 NaCl, 5 mmol/1 ZnCl2, 0.1 g/1 bovine serum albumin, pH
4.4) and digested with Sl-nuclease (0.1 U^g DNA) for 3 h at
37 °C. After dialysis against phosphate-buffered saline (pH 7.2) at
4 °C, the concentration of DNA was determined (A260nm = 1 equ-
als 50 mg/1) (15) and adjusted to 10 mg/1 in phosphate-buffered
saline. Before coating with DNA, the wells of the microtitre plate
were first coated overnight at 4 °C with methylated bovine serum
albumin (10 mg/1 in phosphate-buffered saline 0.1 ml/well). After
washing with phosphate-buffered saline, 0.1 ml of DNA solution
(10 mg/1 in phosphate-buffered saline) was added to each well and
the plate was further incubated overnight at 4 °C. The wells were
then washed three times with phosphate-buffered saline, filled with
1 g/1 gelatin in phosphate-buffered saline and incubated overnight
at 4 °C. After washing, DNA adhering to wells was redigested with
3 kU/1 of Sl-nuclease in phosphate-buffered saline (2 h, room tem-
perature), followed by two washes with phosphate-buffered saline
0.5 g/1 Tween-20.
Preparation of denatured DNA
Denatured DNA was prepared by heating the DNA solution in a
boiling water bath for 15 minutes, then cooling rapidly by immer-
sion in an ice water bath (3). After coating the wells which had
been pre-treated with methylated bovine serum albumin, the pro-
cedure was continued as described for dsDNA.
Preparation of synthetic antigen
Poly([dA-dT] X poly[dA-dT]) was dissolved at 10 mg/1 in phos-
phate-buffered saline and 0.1 ml was added to each well precoated
2) ANA, anti-nuclear antibody;
dsDNA, double stranded deoxyribonucleic acid;
SS, Sj rgen's syndrome;
Sm/RNP, small ribonucleoprotein.
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with methylated bovine serum albumin. The procedure was then
as described for dsDNA, including Sl-nuclease treatment in situ.
Enzyme-linked immunosorbent assay
Sera were diluted 1:400 in phosphate-buffered saline containing
5 g/1, 1 g/I gelatin and 0.5 g/1 Tween-20, then 0.1 ml of diluted
serum was added per well (in triplicate for each serum). After incu-
bation for 2 h at room temperature, the wells were washed three
times with phosphate-buffered saline 0.5 g/1 Tween-20, then 0.1 ml
of alkaline phosphatase-conjugated affinity-purified anti-human Ig
(α, γ. and μ-chain specific) at 1 :5000 was added to each well.
After additional incubation for 2 h at room temperature, the wells
were washed and 0.1 ml of p-nitrophenyl phosphate disodium
(1 g/1 in ethanolamine buffer, pH 9.6) was added to each well. The
reaction was stopped with 3 mol/l NaOH and the absorbance read
at 405 nm in a Benring ELISA Processor. The results of the tripli-
cate samples were reported according to the equation:
Fraction bound = mean A260nm (test serum)
mean (control)
Control sera were obtained from 10 healthy subjects of both sexes
with normal laboratory findings, and were used throughout the
study. Positive control of the test was an anti-nuclear antibody-
positive serum (titre 1:1024) from a patient with an active sys-
temic lupus erythematosus (M. LJ.) that strongly reacted with
dsDNA in an ImmunoDot assay (Gen Bio, San Diego, CA, USA).
Statistics
Data were analysed using a computer statistical package NCSS,
version 5.0, 10/87 (Dr. Jeiry L Hinlze, Kaysvile, UT, USA.). The
statistics included parametric and non-parametric analysis for test-
ing of the differences between the groups.
Results
Our preliminary experiments revealed significantly
higher absorbance values for microtitre wells pre-coated
with methylated-bovine serum albumin to support DNA
binding (p < 0.05), and significantly weaker binding of
sera to dsDNA redigested with Sl-nuclease immediately
before running the test (p < 0.01) (data not shown). In
the final dsDNA ELISA protocol (PVC Microtest III
plates, methylated-bovine serum albumin precoating and
Sl-nuclease redigestion of DNA in situ), the coefficient
of variation between triplicate samples was 4.9%, with
a high correlation of results obtained with the same sera
run on two separate plates (r = 0.941, p < 0.0001).
None of the anti-nuclear antibody-negative subjects in
this study had a detectable level of anti-dsDNA, whereas
76 of 300 (25.3%) anti-nuclear antibody-positive sub-
jects had anti-dsDNA as judged by the sera reactivity of
3 S. D. above the mean of six control human sera run on
each plate (tab. 1). Among these, systemic lupus erythe-
matosus (both active and inactive) was the most frequent
diagnosis (48/77 or 63.2%), including 3 patients in
which a systemic lupus erythematosus was associated
with rheumatoid arthritis and/or vasculitis ("overlapping
syndrome") and four patients (5.2%) provisionally diag-
nosed as suspected systemic lupus erythematosus. In the
non-systemic lupus erythematosus group of patients,
rheumatoid arthritis was the most frequent diagnosis
(7/77, 9.1%), followed by Sjogren's syndrome (2/77,
2.6%) and patients suffering from various autoimmune-
related, malignant and inflammatory diseases. As seen
from table 1, most of the systemic lupus erythematosus
sera had higher median reactivity (188%) than rheuma-
toid arthritis (151%) or those from other non-systemic
lupus erythematosus patients (155%), but the difference
was not statistically significant.
Using a cut-off level of 3 S.D. above the mean of nor-
mal human sera, the specificity of the assay after testing
64 control anti-nuclear antibody-negative sera was
100%. Taking into account all non-systemic lupus ery-
thematosus subjects with a positive anti-nuclear anti-
body finding, the specificity of the assay was 82%, but
this figure reached 91% after including anti-nuclear anti-
body-negative sera. The sensitivity of the assay in the
anti-nuclear antibody-positive systemic lupus erythema-
tosus group with both active and inactive disease (in-
cluding patients with overlapping syndromes, i.e. sys-
temic lupus erythematosus with rheumatoid arthritis
and/or vasculitis) was 66%.
By comparing the reactivities of 50 dsDNA-positive
sera to different DNA preparations at the same coating
concentrations, a high correlation was found between
the binding of sera to dsDNA and dDNA (r = 0.906,
p < 0.0001), dsDNA and dAT (r = 0.930, p < 0.0001)
and between dDNA and dAT (r = 0.892, p < 0.0001)
Tab. 1 Anti-nuclear antibody-positive diseases with a positive
anti-dsDNA result
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 In relation to 3 S. D. above the mean of normal human sera.
b
 Including three patients with an overlapping syndrome, i. e. sys-
temic lupus erythematosus in association with rheumatoid arthri-
tis and/or vasculitis.
c
 Provisonal diagnosis (under verification).
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(tab. 2). However, by comparing the binding of indivi-
dual sera to different DNA preparations, a significantly
higher reactivity to dsDNA than to dDNA (mean, 203%
vs 179%, p < 0.005) and to dAT (mean, 203% vs 180%,
p < 0.001) was found. At the same time, there was no
difference in the reactivity level of individual sera to
dDNA and to dAT (p = 0.7) (tab. 2).
Although the majority of 50 selected anti-dsDNA-posi-
tive sera (37 from systemic lupus erythematosus and 13
from non-systemic lupus erythematosus patients) bound
to dDNA and dAT, 7 of 50 (14%) did not bind to dAT,
whereas 2 of 50 (4%) did not bind to dDNA (tab. 3).
Anti-dsDNA-positive systemic lupus erythematosus sera
(n = 37) showed a similar pattern with 8.1% and 2.7%
of sera lacking the reactivity towards dAT and to dDNA,
respectively. In contrast, the majority (18/24 or 75%) of
anti-dsDNA-negative sera from various diseases were
negative for all three antigens: 3/24 (12.5% bound to
dDNA only (1 systemic lupus erythematosus and 2 rheu-
matoid arthritis patients), whereas 3/24 (12.5%) of non-
systemic lupus erythematosus sera bound to dDNA and
to dAT (tab. 3).
Tab. 2 Comparison of reactivity of 50 anti-dsDNA-positive sera
to dDNA, dsDNA and dAT in an ELISA assay































 dsDNA, double stranded DNA; dDNA, denatured DNA; dAT,
poly[dA-dT] double stranded alternating copolymer.
b
 In relation to 3 S. D. above the mean of normal human sera.
c
 Paired T-test.
Tab. 3 Pattern of anti-nuclear antibody-positive sera binding to
DNA antigens
Sera Anti-nuclear antibody-





























 dsDNA, double stranded DNA; dDNA, denatured DNA; dAT,
poly[dA-dT] double stranded alternating copolymer.
b
 No. of positives/No, tested.
Discussion
By using an ELISA format for the anti-dsDNA anti-
bodies based on Sl-nuclease-treated antigen (15), we
were able to confirm the literature data on the reactiv-
ity of systemic lupus erythematosus and non-systemic
lupus erythematosus sera to dsDN/y (1-4). The speci-
ficity of the assay in a group of anti-nuclear antibody-
positive patients was 82%, and after including anti-
nuclear antibody-negative control sera the overall spec-
ificity was 91%. The assay was positive in 48 of 71
patients with both active and inactive systemic lupus
erythematosus (including three patients with systemic
lupus erythematosus complicated with rheumatoid ar-
thritis and/or vasculitis), reaching a sensitivity of 66%,
which is comparable to that reported in previous
studies (1—4, 15). As observed previously (4, 15), a
rather high proportion of non-systemic lupus erythe-
matosus sera (27.6%) also gave a positive reaction to
dsDNA. Although non-systemic lupus erythematosus
showed weaker binding to dsDNA, the difference was
not significant.
The question, however, arises as to whether this non-
systemic lupus erythematosus dsDNA binding repre-
sents a false result due to the presence of single strands
in our dsDNA preparation. Although we cannot rule out
this possibility, it is interesting to note that a positive
dsDNA finding in systemic lupus erythematosus and
non-systemic lupus erythematosus patients was paral-
leled by dAT binding, an antigen that is apparently free
of ssDNA strands (10). In addition, 3 of 24 anti-dsDNA-
negative sera from various non-systemic lupus erythe-
matosus immune-related diseases bound dDNA and
dAT, a finding that strongly argues against the presence
of single strands in our dsDNA preparation. Radio-
immunoassay showed a strong correlation between the
binding of sera to ss-nuclease-treated natural DNA and
to dAT (10). This correlation disappeared when ss-
nuclease-untreated natural DNA was used, indicating a
contamination of native, nuclease-untreated DNA with
ssDNA (10). It was also hypothesised that nuclease-
treated dsDNA and dAT displayed antigenic similarity
which resulted in high correlation of binding of anti-
dsDNA-positive sera to both antigens. On the basis of
these experiments it was concluded that synthetic anti-
gens such as dAT might offer practical advantages over
natural DNA preparations in detecting anti-dsDNA,
since it contained most of the native DNA specificity
(10). However, others have presented evidence that sys-
temic lupus erythematosus sera contain a mixture of an-
tibodies against different DNA epitopes, one population
binding solely to dsDNA and another to dAT (reviewed
in 1. c. (11)). Our results, obtained in an ELISA solid-
phase, assay, corroborate the finding of high correlation
between the binding of anti-dsDNA-positive sera to
dAT, but stress again that the binding was not 100%
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complementary. In support of this view and in contrast
to the findings of Steinman (10), we actually observed
dAT binding in a proportion (16.7%) of non-systemic
lupus erythematosus ssDNA-positive sera from patients
with rheumatoid arthritis and "mixed collagenosis". This
observation farther corroborates the heterogeneous
pattern of individual anti-DNA specificity, as observed
previously (10—11). It should be noted that the differ-
ences observed might be associated with disease activ-
ity, since dAT binding was mainly observed in patients
with active, but not with inactive nephritis (10). Our
current work is aimed at the comparison of binding of
isolated anti-dsDNA antibodies from patients with sys-
temic lupus erythematosus and non-systemic lupus ery-
thematosus patients to dAT in the context of disease ac-
tivity.
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